Human Genome Sciences Inc Revenue Growth Rates (HGSI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Human Genome Sciences Inc  (HGSI)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

HGSI's Revenue Growth by Quarter and Year

Human Genome Sciences Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

HGSI Revenue (in millions $) FY 2012 FY 2011 FY 2010 FY 2009
4th Quarter December -
3rd Quarter September -
2nd Quarter June 60.34
1st Quarter March 47.13
FY 107.47





HGSI Revenue second quarter 2012 Y/Y Growth Comment
Human Genome Sciences Inc achieved in the second quarter 2012, above Company average Revenue surge of 142.73% year on year, to $ 60.34 millions.

Among companies who have reported second quarter 2012 results in the Medical Laboratories industry only one Company has achieved higher year on year Revenue results in the second quarter 2012. While Human Genome Sciences Inc' s Revenue doubling of 142.73% ranks overall at the positon no. 594 in the second quarter 2012.


HGSI Revenue ( Y/Y Growth %) 2012
 2011 2010 2009
4th Quarter December - 114.11 % - -
3rd Quarter September - -33.01 % - -
2nd Quarter June 142.73 % -35.91 % - -
1st Quarter March 77.38 % -42.87 % - -
FY   - -16.76 % - -

Financial Statements
Human Genome Sciences Inc's second quarter 2012 Revenue $ 60.34 millions HGSI's Income Statement
Human Genome Sciences Inc's second quarter 2011 Revenue $ 24.86 millions Quarterly HGSI's Income Statement


HGSI Revenue (Quarter on Quarter Growth %)

 2012
 2011 2010 2009
4th Quarter December - 33.8 % -58.13 % -
3rd Quarter September - 36.85 % 30.91 % -
2nd Quarter June 28.03 % -6.44 % -16.6 % -
1st Quarter March 3.54 % 24.98 % - -
FY (Year on Year)   - -16.76 % - -


Back to HGSI Growth rate Comparisons >> Back to HGSI Growth rate Comparisons >>


Revenue second quarter 2012 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #2
Healthcare Sector #81
Overall #594

Revenue Y/Y Growth Statistics
High Average Low
51.46 % 14.99 % -16.76 %
(Jun 30 2012)   (Dec 31 2011)
Revenue second quarter 2012 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #2
Healthcare Sector #81
Overall #594
Revenue Y/Y Growth Statistics
High Average Low
51.46 % 14.99 % -16.76 %
(Jun 30 2012)   (Dec 31 2011)

Revenue by Quarter for the Fiscal Years 2009, 2010, 2011, 2012

Human Genome Sciences Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
36.87 % 8.55 % -58.13 %
(Sep 30 2011)  


HGSI's II. Quarter Q/Q Revenue Comment
Human Genome Sciences Inc achieved in the II. Quarter 2012 above company average sequential Revenue jump of 28.03%, to $ 60.34 millions, from $47.13 millions in the first quarter.
HGSI is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Human Genome Sciences Inc's Revenue growth quarter on quarter, overall rank is 477.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #8
Healthcare Sector #87
Overall #477
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #8
Healthcare Sector #87
Overall #477
Revenue Q/Q Growth Statistics
High Average Low
36.87 % 8.55 % -58.13 %
(Sep 30 2011)  


HGSI's II. Quarter Q/Q Revenue Comment
Human Genome Sciences Inc achieved in the II. Quarter 2012 above company average sequential Revenue jump of 28.03%, to $ 60.34 millions, from $47.13 millions in the first quarter.
HGSI is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Human Genome Sciences Inc's Revenue growth quarter on quarter, overall rank is 477.


Human Genome Sciences Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2012)		 12 Months Ending
(Mar 31 2012)		 12 Months Ending
(Dec 31 2011)		 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 187.01 $ 151.53 $ 130.98 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 51.46 % 10.28 % -16.76 % - -
Year on Year Revenue Growth Overall Ranking # 2218 # 0 # # #
Seqeuential Revenue Change (TTM) 23.42 % 15.69 % 22.73 % - -
Seq. Revenue Growth (TTM) Overall Ranking # 594 # 0 # # #


Cumulative Revenue growth Comment
With 51.46% annual Revenue growth, Human Genome Sciences Inc would report a record annual Revenue growth if the fiscal year would end on Jun 30 2012.

In the Healthcare sector 251 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2218.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 2
Healthcare Sector # 252
Overall # 2218

Revenue TTM Y/Y Growth Statistics
High Average Low
51.46 %
 14.99 %
-16.76 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 81
S&P 500 # 594
Cumulative Revenue growth Comment
With 51.46% annual Revenue growth, Human Genome Sciences Inc would report a record annual Revenue growth if the fiscal year would end on Jun 30 2012.

In the Healthcare sector 251 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2218.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 2
Healthcare Sector # 252
Overall # 2218

Revenue TTM Y/Y Growth Statistics
High Average Low
51.46 %
14.99 %
-16.76 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 81
S&P 500 # 594




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
HGSI's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2012 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2012
Horizon Therapeutics Public Limited Company245.17%$ 245.169 millions
Pacira Biosciences inc 239.49%$ 239.494 millions
Sangamo Therapeutics Inc 202.11%$ 202.114 millions
Cardiff Lexington Corporation200.00%$ 200.000 millions
Lifevantage Corp196.55%$ 196.549 millions
Sorrento Therapeutics Inc 192.59%$ 192.588 millions
Fennec Pharmaceuticals Inc 186.67%$ 186.667 millions
Regeneron Pharmaceuticals Inc 182.35%$ 182.348 millions
Inspiremd Inc 166.25%$ 166.250 millions
Nuo Therapeutics, Inc.164.32%$ 164.316 millions
Amicus Therapeutics inc 163.29%$ 163.292 millions
Mimedx Group Inc 153.15%$ 153.149 millions
Veru Inc 146.10%$ 146.102 millions
Alkermes Plc 146.01%$ 146.011 millions
Human Genome Sciences Inc142.75%$ 142.747 millions
Novavax inc 136.69%$ 136.688 millions
Savient Pharmaceuticals Inc133.17%$ 133.165 millions
Wearable Health Solutions, Inc.126.32%$ 126.318 millions
Trius Therapeutics Inc117.70%$ 117.698 millions
Ontrak Inc 104.76%$ 104.762 millions
Repligen Corp102.83%$ 102.828 millions
Amag Pharmaceuticals inc 101.35%$ 101.350 millions
Jazz Pharmaceuticals Plc100.63%$ 100.627 millions
Metropolitan Health Networks Inc98.73%$ 98.734 millions
Akorn Inc96.86%$ 96.861 millions
Titan Pharmaceuticals Inc 95.68%$ 95.683 millions
Fresh Tracks Therapeutics Inc 91.32%$ 91.320 millions
Cocrystal Pharma Inc 91.06%$ 91.064 millions
Ionis Pharmaceuticals Inc 90.71%$ 90.710 millions
Soligenix inc 87.99%$ 87.987 millions


About Human Genome Sciences Inc Revenue Growth Rates (HGSI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.